Pluri Inc. 8-K

What Happened
Pluri Inc. (PLUR) filed a Form 8-K on June 1, 2026 reporting ongoing discussions with the European Investment Bank (EIB) about the EIB finance agreement. The company and its subsidiaries (Pluri Biotech Ltd. and Pluristem GmbH) drew only the first tranche—€20 million—under a facility of up to €50 million; that tranche was disbursed in June 2021, carries 4% annual interest, and was scheduled to be repaid on June 1, 2026. The EIB notified Pluri on April 21, 2026 that it was reserving its rights under the agreement; on May 28, 2026 the EIB confirmed constructive, good‑faith talks and indicated no enforcement action is currently contemplated while discussions continue, which the EIB does not expect to extend beyond July 3, 2026 (but it reserved all rights).

Key Details

• Finance facility: up to €50 million; only €20 million disbursed (June 2021), interest at 4% per annum.
• Scheduled repayment: €20M tranche originally due June 1, 2026.
• Timeline: EIB reserved rights April 21, 2026; confirmed ongoing talks May 28, 2026 and said talks likely to conclude by July 3, 2026.
• EIB stance: no enforcement currently contemplated while talks proceed, but EIB expressly reserved all rights and remedies.

Why It Matters
This disclosure affects Pluri’s near‑term financing and liquidity profile: the company is actively negotiating with a lender about repayment or an extension of a material loan obligation. Investors should note the concrete amounts, the upcoming deadlines (original June 1, 2026 maturity and the EIB’s July 3, 2026 discussion timeline), and that the EIB has reserved the right to take action if talks fail. Pluri also cautioned that there is no assurance a mutually acceptable resolution will be reached; outcomes could affect the company’s cash needs and capital strategy.